



DATE: January 15, 2004 SHEET 1 of 2

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
	6958.US.02	10/635,342
	APPLICANT(S)	
	BaMaung, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	08/06/2003	1614

(Use several sheets if necessary)

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Craig, et al., Chemical Abstract. Database accession no. 135:3311987 CA, XP002262659
C2	Database Crossfire Beilstein. Database accession no. brn 5486092, XP002262661; Tetrahedron Letters 33(39):5737-5740 (1992)
C3	Database Crossfire Beilstein. Database accession no. brn 3650004, XP002262660; Tetrahedron Letters 34(47):7557-7560 (1993)
C4	Database Crossfire Beilstein. Database accession no. brn 4803192, XP002262662; Bull. Chem. Soc. Jpn. 65(2):360-365 (1992)
C5	Database Crossfire Beilstein. Database accession no. brn 1721653, XP002262663; Chem Zentralbl 77(11):765 (1906)
C6	Database Crossfire Beilstein. Database accession no. brn 2430446, XP002262664; Bull. Chem. Soc. Jpn. 49:3181-3184 (1976)
C7	Database Crossfire Beilstein. Database accession no. brn 2968669, XP002262665; J. Med. Chem. 33(12):394-407 (1990)
C8	Database Crossfire Beilstein. Database accession no. brn 2970752, XP002262666; J. Med. Chem. 33(1):694-407 (1990)
C9	Database Crossfire Beilstein. Database accession no. brn 3536828, XP002262667; J. Med. Chem. 33(1):694-407 (1990)
C10	Database Crossfire Beilstein. Database accession no. brn 3609285, XP002262668; Tetrahedron 48(10):1853-1868 (1992)
C11	Database Crossfire Beilstein. Database accession no. brn 4230470, XP002262669; J. Org. Chem. 45(12):2288-2290 (1980)
C12	Database Crossfire Beilstein. Database accession no. brn 4231872, XP002262670; Bioorg. Med. Chem. Lett. 10(20):2305-2310 (2000)
C13	Database Crossfire Beilstein. Database accession no. brn 5486837, XP002262671; Tetrahedron Lett. 33(39):5737-5740 (1992)
C14	Database Crossfire Beilstein. Database accession no. brn 5740104, XP002262672; J. Org. Chem. 50(1):91-97 (1985)
C15	Database Crossfire Beilstein. Database accession no. brn 5862099, XP002262673; Tetrahedron Lett. 34(3):504-504 (1993)
C16	Database Crossfire Beilstein. Database accession no. brn 5906442, XP002262674; Tetrahedron Lett. 34(8):1247-1250 (1993)
C17	Database Crossfire Beilstein. Database accession no. brn 6592217, XP002262675; Tetrahedron Lett. 34(47):7557-7560 (1993)
C18	Database Crossfire Beilstein. Database accession no. brn 6844111, XP002262676; Tetrahedron: Asymmetry 5(2):203-206 (1994)


Database Crossfire Beilstein. Database accession no. brn 7566877, XP002262667; J. Antibiot.
49(9):890-899 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and
not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)




DATE: August 6, 2003 1_ of 1_


Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 6958.US.02	SERIAL NO. (not yet assigned)
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))		APPLICANT(S) N. BaMaung, et al.	
		FILING DATE August 6, 2003	GROUP (not yet assigned)


U.S. PATENT DOCUMENTS


EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	2002-0002152	01/03/02	Craig et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
	B1	99/57098	11.11.99	WO		

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	Griffith et al., "Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin", Chemistry and Biology 4(6):461-471 (1997)
	C2	Sin et al., "The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2", Proc. Natl. Acad. Sci. USA 94:6099-6103 (1997)

EXAMINER 	DATE CONSIDERED Sep 7 2004
---	-------------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)